Active	Status	Sponsor type	Region	Phase	Filter
7 Active 1 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Warshal, David P
NCT05456685: IMGN853 With Carboplatin in Second-line Treatment of FRα Expressing, Platinum-sensitive Epithelial Ovarian Cancer Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022 Sep 2022 - Oct 2022: Data from trial in combination with carboplatin for platinum-sensitive epithelial ovarian cancer at IGCS 2022	Active, not recruiting	2	114	Europe, Canada, US, RoW	Mirvetuximab soravtansine, IMGN853, MIRV, Carboplatin	ImmunoGen, Inc.	High Grade Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer	06/25	12/26
OVATION 2, NCT03393884: Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer Presentation of OVATION 2 data in advanced ovarian cancer Mar 2021 - Mar 2021: Presentation of OVATION 2 data in advanced ovarian cancer	Active, not recruiting	1/2	130	Canada, US	IMNN-001, Carboplatin, Paclitaxel	Imunon	Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	12/24	12/24
Warshall, David
PROFECTA-II, NCT04374630: Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian	Active, not recruiting	2	141	US, RoW	Paclitaxel, Afuresertib, LAE002	Laekna Limited	Platinum-resistant Ovarian Cancer	07/23	06/24